Mylan Sells 46 Million Biocon Shares in Multi-Exchange Block Deals

MUMBAI, INDIA — In a major financial realignment within the international pharmaceutical sector, Mylan Inc, a wholly owned subsidiary of US healthcare giant Viatris, successfully executed the offloading of its entire equity holding in Indian biopharmaceutical leader Biocon Ltd. The massive structural divestment was finalized on Tuesday through synchronized block deals across India's primary stock bourses.

The open-market block execution saw Mylan Inc dump two matching tranches of exactly 45,983,509 equity units totaling approximately 92 million shares on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). The transactions cleared at a uniform transaction value of ₹400 per share, capturing a aggregate transaction size of approximately ₹3,680 crore ($365 million). The institutional exit alters the long-term capital configuration of Bengaluru-headquartered Biocon Ltd, marking the final liquidation of Mylan's historical minority equity presence.

Technical Split and Market Response to the Block Deal

Trading terminal readouts confirmed that the blocks were processed seamlessly during the early morning trading window. On the NSE platform, a distinct single block of 45.98 million shares changed hands at the designated ₹400 mark, with a mathematically identical batch crossing the settlement terminal on the BSE at the exact same value. The execution price of ₹400 per share represented a tight 2.66% discount relative to Monday's closing price of ₹410.95, though it stood comfortably above the initially rumored institutional floor price of ₹378.50 per share.

Despite the large volume of shares hitting the secondary market, institutional demand fully absorbed the block, prompting a strong upward price movement for the underlying stock.

Following the open-market trade confirmation, shares of Biocon Ltd experienced a sharp intraday rally, jumping as much as 6% to hit an early session peak of ₹435 on the BSE, effectively driving the enterprise's market capitalization past the ₹70,500 crore threshold.

17-Year Alliance and the Strategic Restructuring Backstory

The clean exit brings to an end a corporate relationship that began in 2009, when Mylan and Biocon first formed a global alliance to co-develop complex biosimilars and generic insulin analogues for highly regulated Western markets. The commercial partnership evolved into a direct equity holding in 2022, following Biocon Biologics’ landmark $3.3 billion cash-and-stock buyout of Viatris’ global biosimilars business.

The direct equity position in the listed parent entity was initiated when Biocon undertook a major balance sheet restructuring, converting Mylan’s unlisted preference shares into a direct 5.64% stake in Biocon Ltd. With the institutional exit completed, Biocon completes its structural consolidation, integrating its global generics and biosimilars divisions into a streamlined, independent corporate framework spanning more than 120 destination markets.

Official Sources Section

Transaction records and corporate metrics are compiled from the daily block deal transaction sheets generated by the National Stock Exchange of India (NSE) and the BSE Limited. Historical shareholding patterns can be verified via the corporate regulatory filing databases hosted by the Securities and Exchange Board of India (SEBI). Portfolio and structural consolidation reports remain accessible via the global investor communications terminal of Biocon Limited.

Quotes Section

While executive leadership at Viatris maintained a strict policy regarding ongoing market movements, stating:

"We do not comment on immediate market rumors, block deal speculation, or ongoing portfolio adjustments outside of formal regulatory settlement timelines."

Organizers and advisory desks managing the institutional distribution noted:

"The smooth clearing of the 92 million share block across the dual exchanges underscores strong institutional appetite for large-cap Indian pharmaceutical assets. The fact that the blocks cleared at ₹400, well above the baseline floor protection price, demonstrates solid baseline confidence in Biocon’s underlying pipeline."

Why It Matters

The total exit of Mylan removes a significant equity overhang that has weighed on Biocon's stock performance. By successfully transitioning these shares to long-term institutional investors without causing market panic, Biocon can now advance its global biosimilar launches—including its insulin and immunology pipelines—unhindered by impending secondary market liquidations.

Key Facts at a Glance

• Complete Institutional Exit: Mylan Inc has fully dissolved its 5.64% equity stake in biopharmaceutical major Biocon Ltd.

• Dual-Exchange Split: The transaction was executed via matching 46 million share blocks on both the NSE and BSE platforms.

• Transaction Metrics: Shares were transacted at a stable price of ₹400 each, accumulating a gross deal size of roughly ₹3,680 crore.

• Intermediary Desk: Citigroup Global Markets India and Jefferies India acted as the joint bookrunners to guarantee delivery.

FAQ Section

What was the specific clearing price for the Mylan-Biocon block deals?

The entire block of approximately 92 million shares was cleared across the public exchanges at a uniform price of ₹400 per share.

Why did Mylan Inc hold such a substantial stake in Biocon Ltd?

The equity stake originated from a 2022 deal where Biocon Biologics acquired Viatris' global biosimilars business for $3.3 billion, which was later restructured into a direct holding in the parent company.

Will Biocon receive any cash proceeds from this ₹3,680 crore block deal?

No. This was a secondary market transaction where an existing investor sold their shares to other market buyers. The capital goes directly to Mylan Inc.

Source: National Stock Exchange of India (NSE), BSE Limited Exchange Filings, Securities and Exchange Board of India (SEBI) Disclosures